Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Trends in Cancer|December 10, 2021
Impact of tissue-agnostic approvals for patients with sarcomaRoberto Carmagnani Pestana, Juliana Rodrigues Beal, Amanda Parkes, et al.
Case Reports in Oncology|July 12, 2021
Pseudoprogression with Neoadjuvant Immunotherapy for Cutaneous MelanomaDiogo Garcia, Juliana Rodrigues Beal, Daniel Mamere Alvarez, et al.
International Journal of Molecular Sciences|February 25, 2023
Response to Abemaciclib and Immunotherapy Rechallenge with Nivolumab and Ipilimumab in a Heavily Pretreated TMB-H Metastatic Squamous Cell Lung Cancer with CDKN2A Mutation, PIK3CA Amplification and TPS 80%: A Case ReportDouglas Dias E Silva, Guilherme Bes Borba, Juliana Rodrigues Beal, et al.
Einstein (Sao Paulo, Brazil)|January 15, 2026
Response to trastuzumab-deruxtecan in metastatic triple-negative breast cancer with both HER2 mutation and low expressionCaroline Dotto Amarger, Maria Isabel de Sampaio Rabello, Sofia Chaves Skaf, et al.
Biomedicines|March 28, 2026
Very High vs. High Tumor Mutational Burden Across Tumors: Real-World Associations with MSI, Pathway Features, and Immunotherapy OutcomesMaria Fernanda Teixeira, Victoria Tomaz, Lucas Campos Barbosa E Silva, et al.
The Oncologist|October 27, 2025
Immune checkpoint inhibitors combined with tyrosine kinase inhibitors for soft-tissue sarcomas: a systematic review and single-arm meta-analysisDouglas Dias E Silva, Laura Sambugaro Pernomian, Matheus Fernandes, et al.
Einstein (Sao Paulo, Brazil)|June 26, 2024
Prognostic value of programmed cell death ligand 1 (PD-L1) expression in patients with stage III non-small cell lung cancer under different treatment types: a retrospective studyNicoly Marques de Castro, Fernando Moura, Aline Lury Hada, et al.
Breast (Edinburgh, Scotland)|August 6, 2025
Cancer outcomes in patients eligible for adjuvant cyclin-dependent kinase 4 and 6 inhibitors but spared adjuvant chemotherapy by Oncotype Dx: A multicenter retrospective GBECAM 0520 studyLeandro Jonata de Carvalho Oliveira, Daniela Dornelles Rosa, Artur Katz, et al.
JCO Oncology Practice|March 6, 2026
Clinical Impact and Clinicopathologic Correlations of Oncotype DX in Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: Real-World Evidence From a Large Brazilian Cohort (GBECAM 0520)Leandro Jonata de Carvalho Oliveira, Daniella Castro Araújo, Júlio Antonio Pereira de Araújo, et al.
Pageof 1